News
10h
Pharmaceutical Technology on MSNNICE approves GSK’s belantamab mafodotin for blood cancerNHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.
Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results